- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT06694740
Efecto del interferón gamma como tratamiento para la inmunosupresión posagresiva en unidades de cuidados intensivos, un ensayo controlado aleatorizado, doble ciego, bayesiano versus placebo (INFINITY)
The vast majority of serious clinical situations leading to intensive care (septic shock, polytrauma, acute cerebral aggression, major surgery) are characterized by significant systemic inflammation. Recently, the existence of a common immune response pattern to acute aggression has been demonstrated, and with it the existence of a phenomenon known as post-aggressive immunosuppression (PAIS).
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Descripción detallada
The vast majority of serious clinical situations leading to intensive care (septic shock, polytrauma, acute cerebral aggression, major surgery) are characterized by significant systemic inflammation. Recently, the existence of a common immune response pattern to acute aggression has been demonstrated, and with it the existence of a phenomenon known as post-aggressive immunosuppression (PAIS).
This immunological adaptation, initially implemented as a host defense mechanism to protect against an overwhelming systemic reaction, can, if prolonged, lead to multiple complications resulting in significant delayed morbidity and mortality. Diagnosis is based on the use of immuno-inflammatory biomarkers, the most widely studied of which is monocyte expression of major histocompatibility complex type II molecules (mHLA-DR).
We have recently confirmed that PAIS can affect all types of patients admitted to the intensive care unit, but mainly occurs in the most severe patients. We also showed that the occurrence of PAIS was strongly associated with the subsequent occurrence of secondary infection and excess mortality.
Currently, there is no treatment with proven efficacy for PAIS, but several drugs have been shown to restore leukocyte function in-vitro. Several teams have reported the use of immunostimulatory molecules in patients with treatment failure, with a good safety profile and encouraging results. We believe that earlier treatment of patients with proven PAIS could improve their clinical outcome.
Tipo de estudio
Inscripción (Estimado)
Fase
- Fase 2
- Fase 3
Contactos y Ubicaciones
Estudio Contacto
- Nombre: Charles De ROQUETAILLADE, MD
- Número de teléfono: +33 01 49 95 55 68
- Correo electrónico: charles.de-roquetaillade@aphp.fr
Copia de seguridad de contactos de estudio
- Nombre: Benjamin CHOUSTERMAN, Professor
- Número de teléfono: +33 01 49 95 85 18
- Correo electrónico: benjamin.chousterman@aphp.fr
Ubicaciones de estudio
-
-
-
Limoges, Francia, 87000
- Reclutamiento
- Dr Francois Bruno
-
Contacto:
- Bruno Francois, MD
- Número de teléfono: +33 05 55 05 88 41
- Correo electrónico: bruno.françois@chu-limoges.fr
-
Nancy, Francia
- Reclutamiento
- Pr Antoine Kimmoun
-
Contacto:
- Antoine Kimmoun, Professor
- Número de teléfono: +33 03 83 85 14 95
- Correo electrónico: a.kimmoun@chru-nancy.fr
-
Paris, Francia
- Reclutamiento
- Pr Dépret
-
Contacto:
- Pr Dépret François, Professor
- Número de teléfono: +33 01 42 49 95 70
- Correo electrónico: francois.depret@aphp.fr
-
Paris, Francia, 75010
- Reclutamiento
- Pr Benjamin Chousterman
-
Contacto:
- Chousterman Benjamin, Professor
- Número de teléfono: +33 0149958518
- Correo electrónico: benjamin.chousterman@aphp.fr
-
Paris, Francia, 75013
- Reclutamiento
- Pr Constantin Michel
-
Contacto:
- Michel Constantin, Professor
- Número de teléfono: +33 01 42 16 22 59
- Correo electrónico: Jean-michel.constantin@aphp.fr
-
Paris, Francia
- Reclutamiento
- Pr Megarbane
-
Contacto:
- Bruno Megarbane, Professor
- Número de teléfono: +33 01 49 95 84 42
- Correo electrónico: Bruno.megarbane@aphp.fr
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Patient ≥ 18 years old
- SOFA score for first 24 hours post-admission ≥ 6
- Mechanically ventilated at the time of inclusion (non-invasive ventilation (NIV) and high-flow nasal oxygen excluded)
- mHLA-DR< 8,000 AB/C measured between the 5th and 10th day after admission to the intensive care unit
- Patient affiliated to a social security scheme
- Written informed consent from a parent, relative or trusted person. If there is no parent, relative or trusted person, the patient may be included under an emergency procedure and consent to continue will be obtained as soon as possible
Exclusion Criteria:
- Patient with estimated life expectancy of less than 3 months
- Patients with a predicted remaining stay in intensive care < 72 hours
- Patients with an expected prolonged duration of mechanical ventilation: comatose or vegetative patients (admission for severe stroke with Glasgow score < 8, patient resuscitated from an arterial stroke,) patients with tracheotomy for ENT problems, patients suffering from muscular disease (e.g. myopathy), patients on long-term mechanical ventilation
- Pregnant or breast-feeding women
- Contraindication of Imukin (hypersensitivity to interferon gamma-1b or known hypersensitivity to related products, such as another interferon)
- Patients on immunosuppressive therapy, including long-term corticosteroid therapy (>2.5mg/d prednisone equivalent)
- Patients with preexisting severe hepatic( Grade C cirrhosis ) or preexisting kidney failure requiring dialysis
- Patient included in another interventional study (excluding RIPH2 cases not involving prolonged mechanical ventilation)
- People under court protection and protected adults
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Triple
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: interferon gamma-1b injection
Patients randomized to the experimental arm will receive : Recombinant human interferon gamma-1b 2 X 106 IU, injectable solution. Subcutaneous injection every 24 hours for 3 consecutive days (3 total injections) |
|
|
Comparador de placebos: Placebo injection
Patients randomized to the placebo arm will receive saline injectable solution. Subcutaneous injection every 24 hours for 3 consecutive days (3 total injections) |
Patients randomized to the placebo arm will receive saline injectable solution. Subcutaneous injection every 24 hours for 3 consecutive days (3 total injections) |
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
number of days alive without mechanical ventilation
Periodo de tiempo: on Day 28 after drug administration
|
number of days alive without mechanical ventilation on day 28 after randomization or on discharge from intensive care if this occurs before the 28th day |
on Day 28 after drug administration
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Evaluate the efficacy of IFNy in correcting PAIS-defining biological abnormalities (re-ascension of mHLA-DR above 8,000 AB/C) between patients treated with recombinant interferon gamma 1-b versus placebo
Periodo de tiempo: Day 1 to Day 7 and at Day 28 post randomization
|
Evolution of mHLA-DR measured at Day 0, Day 1, Day 2, Day 3, Day 7 and Day 28 or at discharge from intensive care if earlier (Day 0 corresponding to the day of inclusion in the study) between patients treated with recombinant interferon gamma 1-b versus placebo. |
Day 1 to Day 7 and at Day 28 post randomization
|
|
Evaluate, depending on the randomization arm, the kinetics of plasma inflammatory parameters between patients treated with recombinant interferon gamma 1-b versus placebo
Periodo de tiempo: Day 0, Day 3 and at Day 7 post randomization
|
Evolution of inflammation markers (IL-1, IL-2, IL-6, IL-8, TNFa, etc.) measured in plasma at Day 0, Day 3 and Day 7, or at discharge from intensive care if it occurs before (Day 0 corresponding to the day of inclusion in the study) between patients treated with recombinant interferon gamma 1-b versus placebo |
Day 0, Day 3 and at Day 7 post randomization
|
|
mortality at Day 28 and Day 90 after randomization
Periodo de tiempo: Day 28 and Day 90 after randomization
|
Mortality rate at Day 28 and Day 90 after randomization between patients treated with recombinant interferon gamma 1-b versus placebo |
Day 28 and Day 90 after randomization
|
|
incidence of nosocomial infections during intensive care unit stay
Periodo de tiempo: from Day 0 to Day 28 (or the discharge from intensive care)
|
The incidence of nosocomial infections during an ICU stay between patients treated with recombinant interferon gamma 1-b versus placebo |
from Day 0 to Day 28 (or the discharge from intensive care)
|
|
number of days alive whithout antibiotic
Periodo de tiempo: Day 28 after drug administration
|
Number of days alive without antibiotic assessed on day 28 after randomization between patients treated with recombinant interferon gamma 1-b versus placebo |
Day 28 after drug administration
|
|
length of stay in intensive care between patients
Periodo de tiempo: from Day 0 to Day 28 (or the discharge from intensive care)
|
Number of days in intensive care between patients treated with recombinant interferon gamma 1-b versus placebo |
from Day 0 to Day 28 (or the discharge from intensive care)
|
|
- Compare organ failure score (SOFA) kinetics between patients treated with recombinant interferon gamma 1-b versus placebo
Periodo de tiempo: From inclusion to Day 7
|
Kinetics of SOFA score assessed at inclusion and during the 7 days following inclusion between patients treated with recombinant interferon gamma 1-b versus placebo |
From inclusion to Day 7
|
|
Evaluate, depending on the randomization arm, the transcriptomic profile of circulating peripheral blood mononuclear cells count between patients treated with recombinant interferon gamma 1-b versus placebo
Periodo de tiempo: Day 0, Day 3 and Day 7 after randomization
|
Evolution of the transcriptomic profile of circulating peripheral blood mononuclear cells (PBMCs) using scRNAseq analysis measured at Day 0, Day 3 and Day 7 or upon discharge from intensive care if this occurs earlier. |
Day 0, Day 3 and Day 7 after randomization
|
|
Evaluate, depending on the randomization arm the leucocyte count between patients treated with recombinant interferon gamma 1-b versus placebo
Periodo de tiempo: Day 0 to Day 7 and at Day 28 post randomization
|
Evolution and kenetics of the leucocyte count measured at Day 0, Day 1, Day 2, Day 3, Day 7 and Day 28 or at discharge from intensive care if earlier (Day 0 corresponding to the day of inclusion in the study) between patients treated with recombinant interferon gamma 1-b versus placebo |
Day 0 to Day 7 and at Day 28 post randomization
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Silla de estudio: Benjamin Chousterman, Professor, APHP(ASSISTANCE PUBLIQUE DES HOPITAUX DE PARIS
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
- Procesos Patológicos
- Infecciones
- Síndrome de Respuesta Inflamatoria Sistémica
- Inflamación
- Condiciones Patológicas, Signos y Síntomas
- Septicemia
- Péptidos
- Aminoácidos, péptidos y proteínas
- Proteínas
- Factores biológicos
- Péptidos de señalización intercelular y proteínas
- Citocinas
- Interferones
- Linfocinas
- Factores activadores de macrófagos
- Interferón gamma
Otros números de identificación del estudio
- APHP220672
- 2023-506725-11-00 (Ctis)
- 2023 (Subvención/contrato del NIH de EE. UU.)
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .